Jameson S S, Baker P N, Charman S C, Deehan D J, Reed M R, Gregg P J, Van der Meulen J H
The National Joint Registry for England and Wales, 15-17 Tavistock Place, London WC1H 9SH, UK.
J Bone Joint Surg Br. 2012 Jul;94(7):914-8. doi: 10.1302/0301-620X.94B7.29129.
We compared thromboembolic events, major haemorrhage and death after knee replacement in patients receiving either aspirin or low-molecular-weight heparin (LMWH). Data from the National Joint Registry for England and Wales were linked to an administrative database of hospital admissions in the English National Health Service. A total of 156,798 patients between April 2003 and September 2008 were included and followed for 90 days. Multivariable risk modelling was used to estimate odds ratios adjusted for baseline risk factors (AOR). An AOR < 1 indicates that risk rates are lower with LMWH than with aspirin. In all, 36,159 patients (23.1%) were prescribed aspirin and 120,639 patients (76.9%) were prescribed LMWH. We found no statistically significant differences between the aspirin and LMWH groups in the rate of pulmonary embolism (0.49% vs 0.45%, AOR 0.88 (95% confidence interval (CI) 0.74 to 1.05); p = 0.16), 90-day mortality (0.39% vs 0.45%, AOR 1.13 (95% CI 0.94 to 1.37); p = 0.19) or major haemorrhage (0.37% vs 0.39%, AOR 1.01 (95% CI 0.83 to 1.22); p = 0.94). There was a significantly greater likelihood of needing to return to theatre in the aspirin group (0.26% vs 0.19%, AOR 0.73 (95% CI 0.58 to 0.94); p = 0.01). Between patients receiving LMWH or aspirin there was only a small difference in the risk of pulmonary embolism, 90-day mortality and major haemorrhage. These results should be considered when the existing guidelines for thromboprophylaxis after knee replacement are reviewed.
我们比较了接受阿司匹林或低分子肝素(LMWH)治疗的膝关节置换患者的血栓栓塞事件、大出血和死亡情况。来自英格兰和威尔士国家关节注册处的数据与英国国民健康服务体系的医院入院管理数据库相关联。纳入了2003年4月至2008年9月期间的156,798名患者,并随访90天。采用多变量风险模型来估计经基线风险因素调整后的比值比(AOR)。AOR < 1表明LMWH的风险率低于阿司匹林。总计36,159名患者(23.1%)被开具阿司匹林,120,639名患者(76.9%)被开具LMWH。我们发现阿司匹林组和LMWH组在肺栓塞发生率(0.49%对0.45%,AOR 0.88(95%置信区间(CI)0.74至1.05);p = 0.16)、90天死亡率(0.39%对0.45%,AOR 1.13(95% CI 0.94至1.37);p = 0.19)或大出血(0.37%对0.39%,AOR 1.01(95% CI 0.83至1.22);p = 0.94)方面无统计学显著差异。阿司匹林组需要返回手术室的可能性显著更高(0.26%对0.19%,AOR 0.73(95% CI 0.58至0.94);p = 0.01)。在接受LMWH或阿司匹林治疗的患者之间,肺栓塞风险、90天死亡率和大出血方面仅有微小差异。在审查膝关节置换后血栓预防的现有指南时应考虑这些结果。